Evidence map›Paper›PMID 25504651›Full record

ArticleAngewandte Chemie (International ed. in English)2015

Toward the design of a catalytic metallodrug: selective cleavage of G-quadruplex telomeric DNA by an anticancer copper-acridine-ATCUN complex.

Zhen Yu, Menglu Han, James A Cowan

Abstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed.

  1. DNA Scission by Non-Histidine Amino-Terminal Cu(II) and Ni(II) Binding-Like Peptides.Chembiochem : a European journal of chemical biology · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Acridine as an Anti-Tumour Agent: A Critical Review.Molecules (Basel, Switzerland) · 2022
    Review
  6. Article
  7. Activity and Synergy of Cu-ATCUN Antimicrobial Peptides.International journal of molecular sciences · 2022
    Article
  8. Review
  9. Article
  10. Article
  11. Metal-Based G-Quadruplex Binders for Cancer Theranostics.Pharmaceuticals (Basel, Switzerland) · 2021
    Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Zhen YuDepartment of Chemistry and Biochemistry, The Ohio State University, 100 West 18th Avenue, Columbus, OH 43210 (USA).
Menglu Han
James A Cowan

Funding

Novel Catalytic MetalloDrug Targeting IRES RNA for Treatment of HCV InfectionR44AA016712 · NIAAA · METALLOPHARM, LLC · PI COWAN, ADA S · 2011 to 2013
$2.0M
METALLOPEPTIDES AS THERAPEUTIC AGENTSR21HL093446 · NHLBI · OHIO STATE UNIVERSITY · PI COWAN, JAMES A · 2009 to 2010
$408k
Novel Engineered Synthetic Metallodrugs Directed Against HCVR43AA016712 · NIAAA · METALLOPHARM, LLC · PI CHING, SAN · 2007 to 2008
$257k
NHLBI NIH HHS HL093446NHLBI NIH HHS R21 HL093446NIAAA NIH HHS AA016712NIAAA NIH HHS R43 AA016712NIAAA NIH HHS R44 AA016712
6 · The paper itself

Abstract

Telomeric DNA represents a novel target for the development of anticancer drugs. By application of a catalytic metallodrug strategy, a copper-acridine-ATCUN complex (CuGGHK-Acr) has been designed that targets G-quadruplex telomeric DNA. Both fluorescence solution assays and gel sequencing demonstrate the CuGGHK-Acr catalyst to selectively bind and cleave the G-quadruplex telomere sequence. The cleavage pathway has been mapped by matrix assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) experiments. CuGGHK-Acr promotes significant inhibition of cancer cell proliferation and shortening of telomere length. Both senescence and apoptosis are induced in the breast cancer cell line MCF7.

Indexed as

G-QuadruplexesAcridinesAnimalsAntineoplastic AgentsCatalysisCattleCopperDNAMCF-7 CellsSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationTelomereAcridinesAntineoplastic AgentsCopperDNAanticancer agentsbioinorganic chemistrycarbonDNA cleavagepeptides

Identifiers

PMID25504651
PMCPMC4522906

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.